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fully agreeing with the authors' conclusions regarding the relevance of novel immuno therapeutics, but also sharing their con cerns regarding the severe toxicity caused by cytotoxic Tlymphocyte protein 4 (CTLA4) blockade. In response to this article, we wish to offer a few additional insights into the use of immuno therapy for prostate cancer and some possible suggestions for maximizing the efficacy of ipilimumab, while m aintaining an a cceptable drug safety profile.
Although combination therapy (ipili mumab plus cancer vaccine) seems to have an adverseeffect profile comparable to that of ipilimumab alone, 2,3 it is our opinion that combined treatment could introduce an additional level of unpredictable toxi city. In fact, vaccination could trigger bystander (self ) crossreactive immune responses that might then be expanded by CTLA4blockade, with an uncontrollable and unpredictable magnification of auto immune reactions. Cellular vaccines based on allogenic prostate carcinoma cells might activate immune responses against normal epithelial antigens, which could exacerbate autoimmunity against normal mucosae and skin (upon amplification by ipilimumab).
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Viralvectorbased vaccines, on the other hand, could trigger T or B cells to crossreact with mimicking selfantigenic determinants (frequently identified in viral infections), leading to increased autoimmune toxi city.
2,4,5 Thus, we speculate that ipilimumab should be combined with cancer vaccines that specifi cally target antigens expressed uniquely or prevalently by tumour cells. Whole proteins or long peptides derived from tumourspecific antigens-such as cancertestis proteins 6 or molecules linked to neoplastic transformatio n 7,8 -are a ppropriate for such a role.
We agree with the authors that the auto immune toxicity induced by ipilimumab, 
9 Patients with pros tate carcinoma in biochemical failure are ideal candidates for vac cination, as we recently observed during two phase II trials of peptide based cancer vaccines at our institute (L. Rivoltini, unpublished data). 10 Indeed, in our hands, these patients show very limited signs of immune system altera tion (indicated by the low frequency and activity of regulatory T cells and myeloid derived suppressor cells in peripheral blood) and the ability to rapidly develop immunological responses to vaccination, with detectable clinical benefit (in terms of PSA kinetics). However, the issue of vaccine related toxi city could be particularly relevant for these patients, especially when you consider their (relatively high) average age, the indolent nature of their disease, and the frequent need for longterm therapy.
One solution could be to use the vaccine to prime tumourspecific T and B cells and then administer ipilimumab at a low dose (or over a lowintensity schedule) in order to magnify the vaccineinduced immune response. This approach should limit the induction of selfreactive immune cells and, therefore, the full onset of auto immunity. It is worth noting that antibodies that block other negative Tcell regulators (such as PD1 and PDL1) have also demonstrated high efficacy and acceptable toxicity profiles, 11 and could soon be available for combina tion therapy with cancer vaccines. In the near future, urologists will be attempting to transfer data from more than two decades of experimental studies into the clini cal setting. The next steps along this path should be considered carefully in order to maximize therapeutic success for patients, 
